Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2220 Re-Treatment in Transthyretin Amyloid Cardiomyopathy
NCT07213583Phase 2Active, not recruiting
- Sponsor
- Neurimmune
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of cliramitug in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Neurimmune. Started Aug 2025; status: active, not recruiting.
02
Drugs
cliramitug
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT07213583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213583.